Levonelle 1500 microgram tablets and associated names
- Procedure started
- Under evaluation
- CHMP opinion
- European Commission final decision
Table of contents
Overview
On 26 May 2016, the European Medicines Agency completed a review for the emergency contraceptive Levonelle (levonorgestrel, 1500 microgram tablets) and associated names. The Agency's Committee for Medicinal Products for Human Use (CHMP) recommended that when Levonelle is taken together with certain interacting medicines (including the HIV medicine efavirenz and ritonavir, certain medicines for tuberculosis and epilepsy and herbal medicines containing St John's wort) the dose of Levonelle should be doubled. However, Levonelle should only be used with these medicines when a non-hormonal emergency contraceptive (i.e. a copper intrauterine device) is not an option. In order to ensure the correct use of Levonelle, the CHMP recommended including advice on when to take a double dose on the medicine's outer carton as well as in the package leaflet.
Key facts
|
About this medicine
|
|
|---|---|
| Approved name |
Levonelle 1500 microgram tablets and associated names
|
| International non-proprietary name (INN) or common name |
levonorgestrel
|
|
About this procedure
|
|
|---|---|
| Reference number |
EMEA/H/A-13/1427
|
| Type |
Article 13 referrals
This type of referral is triggered for a medicine that has been authorised by mutual recognition or via the decentralised procedure when there is disagreement between Member States on a variation (type II), on the grounds of a potential serious risk to public health. |
| Status |
European Commission final decision
|
|
Key dates and outcomes
|
|
|---|---|
| CHMP opinion date |
26/05/2016
|
| EC decision date |
01/08/2016
|
All documents
-
List item
Levonelle Article-13 referral - Questions and answers on Levonelle and associated names (levonorgestrel, 1500 microgram tablets) (PDF/79.4 KB)
First published: 27/05/2016
Last updated: 09/08/2016
EMA/517526/2016 -
-
List item
Levonelle Article-13 referral - CHMP assessment report (PDF/732.26 KB)
First published: 09/08/2016
Last updated: 09/08/2016
EMA/517526/2016 -
List item
Levonelle Article-13 referral - Annex I (PDF/68.55 KB)
First published: 09/08/2016
Last updated: 09/08/2016 -
-
List item
Levonelle Article-13 referral - Annex II (PDF/95.9 KB)
First published: 09/08/2016
Last updated: 09/08/2016 -
-
List item
Levonelle Article-13 referral - Annex III (PDF/64.12 KB)
First published: 27/05/2016
Last updated: 09/08/2016 -
Description of documents published
Please note that some of the listed documents apply only to certain procedures.
- Overview - lay-language summary of the stage of the procedure
- Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
- Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
- List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
- Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
- List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
- List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
- Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
- Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
- Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
- Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
- Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
- Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
- Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
- Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)
Note that older documents may have different titles.